Losartan Potassium
Product Images NDC 68788-7737

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68788-7737). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium Tab Usp 25mb (Losartan25mg90s)

Label for Losartan Potassium Tab USP 25 mg tablets, generic for Cozaar, manufactured by Camber Pharmaceuticals, Inc. in Piscataway, NJ. The label includes storage instructions, dosage form as oval white tablets imprinted with 'I / 5', and a section for prescription directions in English and Spanish. The labeler is Preferred Pharmaceuticals, Inc.*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over 60 study months for Losartan Potassium and Atenolol. The graph shows time in months on the x-axis and the percentage of patients on the y-axis. Losartan Potassium is represented by a solid line and Atenolol by a dotted line, indicating adjusted risk reduction data.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal/non-fatal stroke over study months, showing two lines labeled Atenolol and Losartan Potassium. The graph includes a note on adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A figure presenting primary endpoint events within demographic subgroups, comparing Losartan Potassium and Atenolol event rates for primary composite and stroke (fatal/non-fatal). The chart uses hazard ratios with confidence intervals displayed as markers, alongside event rates for subgroups defined by age, gender, race, ISH, diabetes, and history of cardiovascular disease.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with an event over 48 months for Losartan potassium versus placebo. The graph shows a higher event rate for the placebo group and includes a risk reduction value of 16.1% with a p-value of 0.022.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of Losartan Potassium depicted with chlorine, hydroxyl, butyl groups, triazole ring, and potassium ion. The diagram illustrates the molecular arrangement of Losartan Potassium, the active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.